HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

M Angela Cenci Selected Research

Oxidopamine (6 Hydroxydopamine)

12/2013Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
1/2012In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
6/2011Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
7/2010Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
3/2010L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
10/2007Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
11/2004Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia.
7/2002L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
1/2002Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


M Angela Cenci Research Topics

Disease

44Dyskinesias (Dyskinesia)
11/2015 - 01/2002
42Parkinson Disease (Parkinson's Disease)
11/2015 - 01/2002
4Parkinsonian Disorders (Parkinsonism)
07/2014 - 06/2004
2Catalepsy
08/2015 - 04/2006
1Dementia (Dementias)
11/2015
1Disease Progression
01/2014
1Movement Disorders (Movement Disorder)
04/2007
1Hyperkinesis
03/2006
1Drug-Induced Dyskinesia (Dyskinesia, Drug Induced)
12/2005

Drug/Important Bio-Agent (IBA)

42Levodopa (L Dopa)FDA LinkGeneric
11/2015 - 01/2002
18Dopamine (Intropin)FDA LinkGeneric
04/2014 - 07/2002
9Oxidopamine (6 Hydroxydopamine)IBA
12/2013 - 01/2002
5metabotropic glutamate receptor 5IBA
12/2013 - 04/2006
3Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA
08/2015 - 04/2006
3gamma-Aminobutyric Acid (GABA)IBA
08/2015 - 11/2004
3Glutamic Acid (Glutamate)FDA Link
08/2015 - 07/2009
3Glutamate Receptors (Glutamate Receptor)IBA
04/2014 - 04/2007
3Serotonin (5 Hydroxytryptamine)IBA
11/2013 - 07/2009
3Bromocriptine (Parlodel)FDA LinkGeneric
11/2009 - 01/2002
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2015 - 08/2011
2Biological Markers (Surrogate Marker)IBA
11/2015 - 11/2010
2Haloperidol (Haldol)FDA LinkGeneric
08/2015 - 04/2006
2PlasticsIBA
04/2015 - 12/2009
22,3,4,5- Tetrahydro- 7,8- dihydroxy- 1- phenyl- 1H- 3- benzazepine (SKF 38393)IBA
12/2013 - 11/2009
2nestin (nestin protein)IBA
08/2011 - 11/2009
2Dopamine Receptors (Dopamine Receptor)IBA
11/2009 - 07/2009
2pyridineIBA
04/2007 - 04/2006
1Muscarinic M4 ReceptorIBA
11/2015
1metabotropic glutamate receptor 4IBA
08/2015
1Dihydroxyphenylalanine (Dopa)IBA
08/2015
1sigma-1 receptor (receptor 1, sigma)IBA
07/2014
1hydroxide ionIBA
12/2013
1Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA
01/2012
1Carbon MonoxideIBA
08/2011
1harpin (messenger)IBA
08/2011
1Retinaldehyde (Retinal)IBA
08/2011
1RNA (Ribonucleic Acid)IBA
08/2011
1ras-GRF1 (ras GRF1)IBA
12/2010
1Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
11/2010
1DeuteriumIBA
10/2010
1fenobamIBA
09/2010
1IEM 1460IBA
07/2010
1CalciumIBA
07/2010
1alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA
07/2010
11- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
07/2010
1AMPA Receptors (AMPA Receptor)IBA
07/2010
1rat endothelial barrier antigenIBA
11/2009
18-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)IBA
07/2009
1Amphetamine (Amfetamine)FDA LinkGeneric
07/2009
1LY 379268IBA
07/2009
15,7-Dihydroxytryptamine (5,7 Dihydroxytryptamine)IBA
07/2009
1Isradipine (Dynacirc)FDA LinkGeneric
03/2009
1Dopamine D1 Receptors (Dopamine D1 Receptor)IBA
10/2007
1SCH 23390IBA
10/2007
1Bromodeoxyuridine (BrdU)IBA
09/2006
1methanesulfonic acid (methanesulfonate)IBA
04/2006
1metabotropic glutamate receptor type 1IBA
04/2006
1LigandsIBA
04/2006
1salicylhydroxamic acid (SHAM)IBA
03/2006
1Messenger RNA (mRNA)IBA
11/2004
1N-Methylaspartate (NMDA)IBA
06/2004
1Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA
06/2004
1Protein Phosphatase 1IBA
05/2003

Therapy/Procedure

6Drug Therapy (Chemotherapy)
03/2014 - 04/2007
6Transplants (Transplant)
11/2013 - 12/2005
3Transplantation (Transplant Recipients)
12/2009 - 12/2005
3Injections
07/2009 - 07/2002
2Denervation
03/2009 - 07/2002